



1. A conjugate of Formula (II), or pharmaceutically acceptable salt thereof:




Formula (II)





wherein:
R⁵⁰ is



or



H(CH₂)_n—, —C(=O)NH((CH₂)_nO)_t(CH₂)_nX₁(CH₂)_n—,
—C(=O)X₂X₃C(=O)((CH₂)_nO)_t(CH₂)_n—,
—C(=O)X₂X₃C(=O)(CH₂)_n—, —C(=O)X₂C(=O)
(CH₂)_nNHC(=O)(CH₂)_n—, —C(=O)X₂C(=O)
(CH₂)_nNHC(=O)((CH₂)_nO)_t(CH₂)_n—, —C(=O)
(CH₂)_nC(R₇)₂—, —C(=O)(CH₂)_nC(R₇)₂SS(CH₂)
NHC(=O)(CH₂)_n—, —(CH₂)_nX₂C(=O)(CH₂)
NHC(=O)((CH₂)_nO)_t(CH₂)_n— or —C(=O)(CH₂)_nC
(=O)NH(CH₂)_n—;
R⁴⁰ is



where the * indicates the point of attachment to Ab;
Ab is an antibody or antigen binding fragment thereof;

R¹ is —NHR² or —NHCHR²R³;R² is —C₃-C₆alkyl or —C₄-C₆alkyl;R³ is L₁OH;L₁ is —(CH₂)_m—;L₂ is —(CH₂)_n—, —((CH₂)_nO)_t(CH₂)_n—, —(CH₂)_nX₁
(CH₂)_n—, —(CH₂)_nNHC(=O)(CH₂)_n—, —(CH₂)_nNHC(=O)(CH₂)_nC(=O)NH(CH₂)_n—, —((CH₂)_nO)_t
(CH₂)_nNHC(=O)(CH₂)_n—, —C(=O)(CH₂)_n—,—C(=O)((CH₂)_nO)_t(CH₂)_n—, —C(=O)((CH₂)_nO)_t
(CH₂)_nX₁(CH₂)_n—, —C(=O)((CH₂)_nO)_t(CH₂)_nNHC
(=O)(CH₂)_n—, —C(=O)((CH₂)_nO)_t(CH₂)_nC(=O)N

—S—, —NHC(=O)CH₂—, —S(=O)₂CH₂CH₂—,
—(CH₂)₂S(=O)₂CH₂CH₂—, —NHS(=O)₂CH₂CH₂—,
—NHC(=O)CH₂CH₂—, —CH₂NHCH₂CH₂—,
—NHCH₂CH₂—,

